A new way
to treat dogs
with cancer.
NaNots are injectable nanoparticles that clear molecules used by tumors to evade the immune system — so dogs can fight off their own tumors.
NaNots are injectable nanoparticles that clear molecules used by tumors to evade the immune system — so dogs can fight off their own tumors.
Almost none of them are treated.
We can change that.
Existing treatments were designed for humans and adapted imperfectly for dogs. They are expensive, highly toxic, and often ineffective. Faced with poor prognosis and significant suffering, veterinarians and owners routinely choose euthanasia as the most humane option.
This is not a market problem. It is a therapy problem. The demand for a better option is overwhelming — and is almost entirely unmet.
| Feature | Chemotherapy | Radiation | Immunotherapy | NaNots |
|---|---|---|---|---|
| Efficacy | Moderate | Moderate | Limited | High efficacy predicted, mechanism proven |
| Side effects | Severe | Severe | Moderate | Minimal |
| Cost per course | $5K–$20K | $10K–$20K | $15K–$25K+ | ~$3,000 |
| Lasting immune benefit | No | No | Limited | Yes — activates host immunity |
| Canine-optimized | No | No | Partial | Yes — first of its kind |
Inside NaNots:
NaNots are adsorptive nanoparticles, 150 nanometers in diameter – 1/500th the width of a hair. They're fabricated from biodegradable materials and are both scalable & safe.
Injected like a drug, cleared by macrophages.
Essentially a molecular sponge.
Cancer cells secrete sTNF-Rs and sPD-L1 proteins that neutralize incoming immune attack and prevent tumor destruction.
A simple IV injection delivers trillions of NaNots containing capture agents that bind canine tumor-generated immune inhibitors.
NaNots adsorb up to 95% of circulating immune inhibitors within minutes. Blood-level depletion drives tumor microenvironment depletion.
Once immune inhibitors are removed, immune cells can infiltrate and destroy the cancer – without toxic drugs or radiation.
Liver macrophages break down NaNots naturally. No morbidity or mortality observed in rodent studies at 100× the planned canine dose.
Our target canine cancers represent >50% of all cases, including lymphoma, hemangiosarcoma, melanoma, osteosarcoma (bone) & other solid tumor types.
| Feature | Chemotherapy | Radiation | Immunotherapy | NaNots |
|---|---|---|---|---|
| Efficacy | Moderate | Moderate | Limited | High efficacy predicted, mechanism proven |
| Side effects | Severe | Severe | Moderate | Minimal |
| Cost per course | $5K–$20K | $10K–$20K | $15K–$25K+ | ~$3,000 |
| Lasting immune benefit | No | No | Limited | Yes — activates host immunity |
| Canine-optimized | No | No | Partial | Yes — first of its kind |
...cancer recurrences in 6 dogs treated with Ultrapheresis. All tumors regressed fully. None recurred in 1–4 years of follow-up.
Ultrapheresis was a blood filtration device that depleted all molecules below a certain size, including sTNF-Rs & sPD-L1. Results in dogs demonstrated the power of treating cancer by clearing immune inhibitors from blood, leading to the 2nd generation device...
...overall Response Rate (ORR) in 102 late-stage human cancer patients, with a broad range of cancer types, treated by Immune Pheresis. Contrast this with the 16% ORR of Keytruda – the best selling cancer drug of all time – when it was in Phase-1.
Immune Pheresis is a more refined version of Ultrapheresis in that it depletes sTNF-Rs specifically – just like NaNots.
...more metastasis-free survivors with NaNots vs. the mouse equivalent of Keytruda in a triple-negative breast cancer model.
NaNots are the most advanced method yet developed for depleting disease drivers from blood. NaNots deplete targets faster, more deeply and for much longer than Immune Pheresis, all via simple IV injection – no external device required.
A lean, focused proof-of-concept study designed to trigger rapid acquisition by a global animal health company.
Engineer canine-specific NaNots using nanobody capture agents. Scale production & conduct PK/safety testing.
PoC study in 3 cohorts at top veterinary research centers. CT imaging at weeks 0, 8 & 16 per RECIST criteria.
Top-performing regimen tested in additional dogs — building a compelling combined dataset for best protocol.
NK9 sold to global animal health pharma. Acquirer handles regulatory approvals. Investors collect returns.
Targeting soluble TNF receptors — the same proteins depleted in Immune Pheresis trials that achieved 60% ORR in humans and full tumor regression in dogs.
Targeting soluble PD-L1, elevated in dogs with cancer. NaNots deplete only the soluble form — leaving membrane PD-L1 outside the tumor unaffected, reducing side effects.
NaNots against both sTNF-Rs and sPD-L1 are combined in this regimen and tested in the same number of dogs as the other cohorts.
The best protocol from above will be tested in additional dogs,
to create an expanded dataset to support NK9 acquisition.
NaNots don't compete for existing market share. They convert euthanasia cases into treatment cases.
sTNF-Rs & sPD-L1 shown to suppress immune responses across 20+ years of independent studies; depletion leads to anti-tumor efficacy.
Multiple studies of NaNots against these targets have shown >95% target depletion in minutes.
NK9 receives exclusive, royalty-free, perpetual license for these NaNots for canine oncology.
KindredBio ($440M), Invetx ($531M), PetMedix ($210M) — all pre-approval, all in this space.
Assuming NaNots work as well in dogs with cancer as prior studies in other species would suggest, the result will be a world-wide phenomenon — not just a breakthrough product of enormous value, but a breakthrough in our ability to extend the lives and preserve the health of our most devoted and loyal companions.
Deep expertise in nanomedicine, oncology, and veterinary development — and a personal stake in what we're building.
NaNot inventor & company founder. Led commercialization of pet cloning starting 1998. Co-founded Viagen (acquired by Intrexon). Led early generative A.I. development project. Cancer research since 2008. Dozens of patents. Princeton, BA 1983.
33+ years as a biopharma leader. Inventor/developer of PROVENGE® and DAXXIFY®. Former CEO of Amphivena & Parvus Therapeutics. Ph.D. from Johns Hopkins. Cancer Research Institute Fellow at Stanford. 50+ patents. Active member of AACR, SITC and AAI.
NaNotics co-founder. Expert in micro/nano bioengineering; also expert in IP development with 40+ patents. Pioneer in microfluidics & chemical sensors. Multidisciplinary expertise across physical chemistry and nanomedicine. Ph.D. Newcastle; BA Cambridge Physics.